Evidence map›Paper›PMID 32702098›Full record

ArticleThe Journal of infectious diseases2020

Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome.

Katherine W Lam, Kenneth W Chow, Jonathan Vo, Wei Hou, Haifang Li, Paul S Richman, Sandeep K Mallipattu, Hal A Skopicki, Adam J Singer, Tim Q Duong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 15 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 15 syntheses or guidelines pooled it.

  1. Pooled it
  2. Discontinuation of Antihypertensive Drug Use Compared to Continuation in COVID-19 Patients: A Systematic Review with Meta-analysis and Trial Sequential Analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Katherine W LamDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Kenneth W ChowDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Jonathan VoDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Wei HouDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Haifang LiDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Paul S RichmanDepartment of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Sandeep K MallipattuDepartment of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Hal A SkopickiDepartment of Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Adam J SingerDepartment of Emergency Medicine, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.
Tim Q DuongDepartment of Radiology, Renaissance School of Medicine, Stony Brook University, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study investigated continued and discontinued use of angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB) during hospitalization of 614 hypertensive laboratory-confirmed COVID-19 patients.

methodsDemographics, comorbidities, vital signs, laboratory data, and ACEi/ARB usage were analyzed. To account for confounders, patients were substratified by whether they developed hypotension and acute kidney injury (AKI) during the index hospitalization.

resultsMortality (22% vs 17%, P > .05) and intensive care unit (ICU) admission (26% vs 12%, P > .05) rates were not significantly different between non-ACEi/ARB and ACEi/ARB groups. However, patients who continued ACEi/ARBs in the hospital had a markedly lower ICU admission rate (12% vs 26%; P = .001; odds ratio [OR] = 0.347; 95% confidence interval [CI], .187-.643) and mortality rate (6% vs 28%; P = .001; OR = 0.215; 95% CI, .101-.455) compared to patients who discontinued ACEi/ARB. The odds ratio for mortality remained significantly lower after accounting for development of hypotension or AKI.

conclusionsThese findings suggest that continued ACEi/ARB use in hypertensive COVID-19 patients yields better clinical outcomes.

Indexed as

Acute Kidney InjuryAgedAged, 80 and overAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFemaleHospitalizationHumansHypertensionMaleMiddle AgedPandemicsAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonistsacute kidney injuryangiotensin-converting enzyme inhibitorsangiotensin II receptor blockershypotensiontroponin

Identifiers

PMID32702098
PMCPMC7454718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.